Hepatitis A laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:


===Serologic Tests===
===Serologic Tests===
Serologic testing is required to confirm the [[diagnosis]] of acute [[HAV infection]].
Serologic testing is required to confirm the [[diagnosis]] of acute [[HAV infection]]. Serologic testing to detect [[immunoglobulin M]] ([[IgM]]) antibody to the capsid proteins of [[HAV]] (IgM anti-HAV) is required to confirm a diagnosis of acute HAV infection The following antibodies are searched for:


* [[Immunoglobulin M]] ([[IgM]]) anti-HAV:<ref>Bower WA, Nainan OV, Margolis HS. Duration of viremia in naturally-acquired hepatitis A viral infections. [Abstract 103] In: Abstracts of the Infectious Diseases Society of America 35th Annual Meeting. Alexandria, VA: Infectious Diseases Society of America, 1997.</ref><ref name="pmid3759243">{{cite journal |author=Liaw YF, Yang CY, Chu CM, Huang MJ |title=Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak |journal=[[Infection]] |volume=14 |issue=4 |pages=156–8 |year=1986 |pmid=3759243 |doi= |url= |accessdate=2012-02-28}}</ref>
* [[Immunoglobulin M]] ([[IgM]]) anti-HAV:<ref>Bower WA, Nainan OV, Margolis HS. Duration of viremia in naturally-acquired hepatitis A viral infections. [Abstract 103] In: Abstracts of the Infectious Diseases Society of America 35th Annual Meeting. Alexandria, VA: Infectious Diseases Society of America, 1997.</ref><ref name="pmid3759243">{{cite journal |author=Liaw YF, Yang CY, Chu CM, Huang MJ |title=Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak |journal=[[Infection]] |volume=14 |issue=4 |pages=156–8 |year=1986 |pmid=3759243 |doi= |url= |accessdate=2012-02-28}}</ref>
Line 22: Line 22:
:* Confers lifelong protection against the disease  
:* Confers lifelong protection against the disease  


Two [[serologic]] tests are licensed for the detection of antibodies to HAV:
Two [[serologic]] tests are licensed for the detection of antibodies to [[HAV]]:
1) IgM anti-HAV
1) [[IgM]] anti-[[HAV]]
2) Total anti-HAV (IgM and IgG anti-HAV)
2) Total anti-[[HAV]] (IgM and IgG anti-HAV)


In the majority of patients, IgM anti-HAV declines to undetectable levels <6 months after infection. However, persons who test positive for IgM anti-HAV >1 year after infection have been reported, as have likely false-positive tests in persons without evidence of recent HAV infection.
In the majority of patients, IgM anti-HAV declines to undetectable levels less than 6 months after [[infection]]. However, persons who test positive for IgM anti-HAV more than 1 year after [[infection]] have been reported, as have likely [[false-positive]] tests in persons without evidence of recent HAV infection.


Total anti-HAV testing is used in epidemiologic studies to measure the prevalence of previous infection or by clinicians to determine whether a person with an indication for pre-exposure prophylaxis is already immune.
Total anti-HAV testing is used in epidemiologic studies to measure the prevalence of previous [[infection]] or by clinicians to determine whether a person with an indication for pre-exposure [[prophylaxis]] is already [[immune]].


Sensitive tests for [[IgM]] and [[immunoglobulin G]] ([[IgG]]) anti-HAV in saliva have been developed but are not licensed in the United States.
Sensitive tests for [[immunoglobulin M]] ([[IgM]]) and [[immunoglobulin G]] ([[IgG]]) anti-HAV in saliva have been developed but are not licensed in the United States.
 
* Serologic testing to detect immunoglobulin M (IgM) antibody to the capsid proteins of HAV (IgM anti-HAV) is


[[Image:HAV Infection.png|left|thumb|300px|Serum IgG, IgM and ALT following Hepatitis A virus infection]]
[[Image:HAV Infection.png|left|thumb|300px|Serum IgG, IgM and ALT following Hepatitis A virus infection]]

Revision as of 14:36, 28 July 2014

Hepatitis Main Page

Hepatitis A

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis A from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Ultrasound

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Hepatitis A laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis A laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis A laboratory findings

CDC on Hepatitis A laboratory findings

Hepatitis A laboratory findings in the news

Blogs on Hepatitis A laboratory findings

Directions to Hospitals Treating Hepatitis A

Risk calculators and risk factors for Hepatitis A laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Laboratory Findings

Hepatitis A cannot be differentiated from other types of viral hepatitis on the basis of clinical or epidemiologic features alone.


Serologic Tests

Serologic testing is required to confirm the diagnosis of acute HAV infection. Serologic testing to detect immunoglobulin M (IgM) antibody to the capsid proteins of HAV (IgM anti-HAV) is required to confirm a diagnosis of acute HAV infection The following antibodies are searched for:

  • Required to confirm the diagnosis of acute HAV infection
  • In most persons, it becomes detectable 5-10 days before the onset of symptoms and can persist for up to 6 months after infection
  • Appears early in the course of infection
  • Remains detectable for the person's lifetime
  • Confers lifelong protection against the disease

Two serologic tests are licensed for the detection of antibodies to HAV: 1) IgM anti-HAV 2) Total anti-HAV (IgM and IgG anti-HAV)

In the majority of patients, IgM anti-HAV declines to undetectable levels less than 6 months after infection. However, persons who test positive for IgM anti-HAV more than 1 year after infection have been reported, as have likely false-positive tests in persons without evidence of recent HAV infection.

Total anti-HAV testing is used in epidemiologic studies to measure the prevalence of previous infection or by clinicians to determine whether a person with an indication for pre-exposure prophylaxis is already immune.

Sensitive tests for immunoglobulin M (IgM) and immunoglobulin G (IgG) anti-HAV in saliva have been developed but are not licensed in the United States.

Serum IgG, IgM and ALT following Hepatitis A virus infection
  • HAV RNA can be detected in the blood and stool of the majority of persons during the acute phase of infection by using nucleic acid amplification methods, and nucleic acid sequencing has been used to determine the relatedness of HAV isolates for epidemiologic investigations. However, only a limited number of research laboratories have the capacity to use these methods.
  • HAV RNA can be detected in the blood and stool of most persons during the acute phase of infection by using nucleic acid amplification methods, and nucleic acid sequencing has been used to determine the relatedness of HAV isolates. [4] However, these methods, available in only a limited number of research laboratories, generally are not used for diagnostic purposes.

Liver Function Tests

Liver enzymes such as aminotransferase and alkaline phosphatase are elevated with high levels of serum total and direct bilirubin among patients with Hepatitis A.[5] The serum levels of alanine aminotransferase (ALT) are usually higher than aspartate aminotransferase (AST). Bilirubin levels tends to increase after the elevation of serum aminotransferase.

Other Laboratory Findings

Liver Biopsy

The role of a liver biopsy is minimal in the diagnosis of hepatitis A. It may be used in cases involving chronic relapsing hepatitis A or when the diagnosis is unclear.


References

  1. Bower WA, Nainan OV, Margolis HS. Duration of viremia in naturally-acquired hepatitis A viral infections. [Abstract 103] In: Abstracts of the Infectious Diseases Society of America 35th Annual Meeting. Alexandria, VA: Infectious Diseases Society of America, 1997.
  2. Liaw YF, Yang CY, Chu CM, Huang MJ (1986). "Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak". Infection. 14 (4): 156–8. PMID 3759243. |access-date= requires |url= (help)
  3. Stapleton JT (1995). "Host immune response to hepatitis A virus". The Journal of Infectious Diseases. 171 Suppl 1: S9–14. PMID 7876654. Retrieved 2012-02-28. Unknown parameter |month= ignored (help)
  4. Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, Goldstein ST, Gensheimer KF, Bell BP, Shapiro CN, Alter MJ, Margolis HS (1999). "A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team". The New England Journal of Medicine. 340 (8): 595–602. doi:10.1056/NEJM199902253400802. PMID 10029643. Retrieved 2012-02-28. Unknown parameter |month= ignored (help)
  5. Tong MJ, el-Farra NS, Grew MI (1995). "Clinical manifestations of hepatitis A: recent experience in a community teaching hospital". The Journal of Infectious Diseases. 171 Suppl 1: S15–8. PMID 7876641. Retrieved 2012-03-08. Unknown parameter |month= ignored (help)

Template:WH Template:WS